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pital admissions between the 2 groups. Total mean medical costs
were signiﬁcantly higher in MLD patients ($35,173) compared
to HCC patients ($22,465, p < 0.001). Inpatient costs con-
tributed 61% ($13,687) to the total cost in HCC patients com-
pared to 45% ($14,349, p < 0.05) in MLD patients. Conversely,
46% ($16,006) of the total cost in MLD patients was due to
physician costs (including chemotherapy), compared to only
27% ($6115, p < 0.001) in HCC patients. CONCLUSIONS:
Among Medicare patients newly diagnosed with HCC or MLD,
signiﬁcantly higher 1-year health resource use and medical costs
were found in MLD patients. The difference in overall costs was
due primarily to higher physician (including ofﬁce) costs among
MLD patients. These ﬁndings provide important new data for
evaluating the economic impact of treating HCC and MLD
patients in the Medicare population.
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OBJECTIVES: To investigate the health care utilization and
direct medical costs associated with treating early and late stage
oropharyngeal cancer within the ﬁrst year following diagnosis.
METHODS: A retrospective database analysis was conducted
using California Medicaid claims data merged with mortality
data for the years 1995 to 2003. Patients diagnosed with oropha-
ryngeal cancer were identiﬁed using a 6-month wash-out period
and were either continuously eligible for 12 months following
diagnosis or had a recorded death within that year. Utilization
of health care resources was assessed and direct Medicaid pay-
ments were calculated. Subgroup analysis was preformed on
patients with early and late stage disease as deﬁned by their
cancer treatment. Using treatment to deﬁne tumor stage was in
accordance to Modi’s 2005 review of the standard of care for
treatment of squamous cell carcinoma of the head and neck.
Regression was used to determine signiﬁcant predictors of total
one year Log cost of care in this population. RESULTS: We iden-
tiﬁed 322 who were diagnosed and treated for oropharyngeal
cancer. The median one year cost of care for these Medicaid
patients was $26,763. Total health care spending was 38.03%
higher for patients who received early stage treatment and died
within the year (p = 0.0164), 53.54% higher for patients who
received late-stage treatment and survived the year (p = 0.0036),
and 85.29% higher for patients who had late stage treatment
and died within the year (p = 0.0033) compared with patients
who received early stage treatment and survived. Comorbidities
and their interaction with age were also signiﬁcant (p < 0.01) in
predicting Log costs. CONCLUSIONS: Oropharyngeal cancer is
a signiﬁcant cost from the insurer’s perspective. In addition to
improved prognosis and quality of life, early diagnosis may
reduce the cost of care to the insurer and therefore efforts should
be made to diagnose oral tumors at an earlier stage.
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OBJECTIVES: AML in the elderly is characterized by high short-
term mortality and economic burden, with hospitalizations as
the main driver. We examined clinical and economic outcomes
of the initial hospitalization in an elderly cohort with newly-
diagnosed AML. METHODS: An analysis of the 2002 Premier
Perspective inpatient database was performed in patients >65
years with a new diagnosis of AML. RESULTS: A total of 509
(46% female) patients accounting for 803 hospital admissions,
met the inclusion criteria. There was an equal proportion of
patients in the groups aged 65–74 and >75. Of the 183 (36%)
patients receiving chemotherapy (CT) on ﬁrst admission, 41%
received standard induction (SI), 31% non-SI and 27% hydrox-
yurea (H). Among CT group, more SI patients were younger than
non-SI patients (73% and 51% 65–74yrs, respectively), while
fewer non-CT and H patients were younger (39% and 32%, 65–
75yrs, respectively). CT patients were less likely to have comor-
bidities (8%) compared to non-CT (17%). Sixty-three percent of
all hospital deaths occurred during the ﬁrst hospitalization with
the majority occurring within the ﬁrst two weeks. Overall hos-
pital death rate during the ﬁrst hospitalization was 29%, but
higher in SI (39%) and non-SI (40%). Longer hospital stay in SI
and non-SI patients, 30 and 21 days, respectively, was also
observed, compared to 12 days overall. Mean (SD) costs of ﬁrst
hospitalization was $36,866 ($33,045) and $8936($10,340) for
CT and non-CT, respectively but comparable on a per day basis.
CONCLUSIONS: AML remains devastating and costly. Hospi-
tal mortality is high during the initial hospitalization, and a sub-
stantial proportion of deaths in this period occurs within the ﬁrst
two weeks.
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OBJECTIVES: With availability of several colorectal cancer
screening tools, the cost-effectiveness of population-based
screening programmes is of interest. The goal of this study was
to estimate the per-procedure cost of conventional colonoscopy
(COL) and ﬂexible sigmoidoscopy (SIG) in an outpatient
endoscopy clinic. METHODS: An activity based costing
approach was carried out using time-and-motion techniques on
104 COL and 48 SIG procedures performed in St. Paul’s Hos-
pital (SPH) between July and October 2004. Observation began
with patient registration in the clinic and ended with patient dis-
charge. Direct costs, including nursing and physician time, sup-
plies and medications, were estimated. Indirect costs included
physician and pathology fees, scope repair and cleaning
expenses. Hospital overhead costs were determined through SPH
ﬁnance department. Total cost was calculated as the sum of
direct, indirect and overhead costs. Student’s t-tests were per-
formed to determine any signiﬁcant differences (P < 0.10) of
mean total cost between groups derived from baseline variables.
Linear regression analysis of cost was also conducted. All costs
are reported in 2004 Canadian dollars. RESULTS: Mean age of
patients was 56 (22; 88) years for COL and 51 (17; 90) years
for SIG. Mean total time was 189 (106; 317) minutes for COL
and 53 (14; 111) minutes for SIG. Mean procedure time for COL
and SIG was 34 (18; 61) minutes and 14 (7; 35) minutes, respec-
tively. Total cost was $522 ($360; $679) for COL and $176
($105; $287) for SIG. Physician and pathology fees accounted
for 61% of total cost for COL and 58% for FSIG. Number of
biopsies and total time have signiﬁcant predictive power on total
cost for both procedures. Sex and number of polypectomies are
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signiﬁcant for COL. CONCLUSIONS: Detailed costing of such
procedures provide useful estimates of health resource use which
can be applied in economic evaluations of CRC screening.
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In Mexico, breast cancer is the second most frequent cancer in
oncology patients so high quality healthcare services and an efﬁ-
cient resource use is a priority. Currently, Mexican costs of dif-
ferent oncology treatments are general and incomplete.
OBJECTIVES: To estimate in detail multiple breast cancer treat-
ments costs in two oncology hospitals in the Mexican Institute
of Social Security in Mexico City. METHODS: A case type
model was constructed to identify resource use with the aid of
expert opinion in radiotherapy, surgical, and chemotherapy ser-
vices in two high speciality oncology hospitals (“Centro Médico
Nacional La Raza” and “Centro Médico Nacional Siglo XXI”),
during the last six-months of 2005. The total costs of each treat-
ment was established with the case-mix technique and the
research perspective was that of the health care payer’s. Direct
costs include: drugs, health staff wages, instrumental and
medical equipment, laboratory and gabinet exams, and other
resources for medical services. Indirect costs include: energy,
water, gas, infraestructure, administrative costs, and others sig-
niﬁcant overheads. RESULTS: The costs estimation for surgery
procedures were: Lumpectomy US$1075 and Mastectomy
US$3291.80. In radiotherapy services tangential ﬁelds (TF) had
a mean cost per intervention of US$849.90 and a breast com-
plete cycle (BCC) was estimated in US$1284.10. Chemotherapy
treatments showed different mean costs: CMF (6 cycles)
US$624.90; FEC (4 cycles) US$1682.50; FEC (6–8 cycles)
US$2847.30; Navelbine (6 cycles) US$3583.80, CarboGem (6
cycles) US$5374.70; Capacitabine (6 cycles) US$6279.60; 
Epirubicina + Taxotere (4 cycles) US$11,607.30, and
Trastuzumab US$16,572. CONCLUSIONS: Total costs of treat-
ment per patient with breast cancer was estimated in Mexico
(one surgical, radiotherapy and chemotherapy procedure was
always included). The cheapeast treatment scenario included:
lumpectomy, TF and CMF with a cost of US$2264.20 and the
highest cost scenario was found using rebuilding surgery, BCC
and Trastuzumab with a cost of US$20,477.10.
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OBJECTIVES: Three-dimensional conformal radiotherapy and
intensity-modulated radiotherapy permit more accurate con-
forming of treatment beams to the shape of target organs; other
sources of geometric variations, such as patient movement, posi-
tioning uncertainties, and organ motion, can result in complica-
tions due to irradiation of normal tissues. This assessment
evaluated the evidence on the Calypso® 4D Localization System
(“System”). This is a real-time three-dimensional target tracking
system that was developed to aid in tumor target localization
during radiation therapy. It utilizes implanted wireless transpon-
ders that respond to an AC activation wave with a low-energy
radio-frequency return signal that can be used to obtain real-time
positional information of the target organ. METHODS: The
MEDLINE® database and Cochrane Library were searched for
all articles published during the period commencing January
1995 through October 2005 using subject headings and terms.
A total of nine abstracts reporting limited data on the mecha-
nism and accuracy of the System were presented at the 2004 and
2005 annual meetings of the ASTRO. Comparators included
electronic portal imaging devices (EPID); CT, including standard
CT and CT-on-rails; ultrasound, including B-mode Acquisition
and Targeting (BAT®); and X-ray, including the CyberKnife®.
RESULTS: Initial clinical results indicated eleven of 20 evaluable
patients were localized and tracked with the System; compared
to standard radiographic x-rays, localization and tracking by the
System demonstrated a mean 3D difference of 1.5mm (SD 0.9).
Two of 11 (18%) patients exhibited signiﬁcant organ motion
exceeding 5mm over an eight-minute tracking period with the
excursions persisting over one minute. Preliminary data were
available for ﬁve patients (193 fractions) from a second cohort
which conﬁrmed early ﬁndings. PROM also indicated patient
preference for the System. CONCLUSION: 4D tracking and
localization improves target organ irradiation in comparison to
existing technologies because by improved detection of organ
motion in real time.
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OBJECTIVE: The issue of efﬁciency in providing treatment is a
critical in the current environment of escalating cost of medical
care and rising number of uninsured and underinsured. Improv-
ing efﬁciency would give a room for charity and uncompensated
care for the indigent population. To describe any variation in the
efﬁciency of proﬁt and non-proﬁt Cancer Centers. These centers
usually are associated with a national or local hospital chain,
Policy implications due to these variations would be in form of
the level of service and access for the community and indigent
populations. METHODS: Unit of analysis: Cancer Centers (CC).
Cross-sectional study for the year, 1995 Dependent variables:
Full-time Equivalent Employee Regression analysis and descrip-
tive statistics will be used in this study. RESULTS: For-Proﬁt
Cancer Center showed more cost cutting and efﬁcient way to
operate than Non-Proﬁt centers. The most efﬁcient centers were
located in the Western region of the country followed by North-
east, the Midwestern and region and the southern region of
United States. Cancer centers with average number of beds equal
or below 50 beds were the most efﬁcient in terms of minimizing
cost. This indicates that Cancer centers suffer from diseconomy
of scale. CONCLUSIONS: The importance of the study stems
from the debate over the effect of the healthcare cost on access
to healthcare. If efﬁciency is not used to improve the cost of treat-
ment, and the services provided by the Cancer Center, then
society might be better off by having a single payer system to
pressure for more efﬁciency and less disparity in the healthcare
system. This study must be taken with a grain of salt due it lim-
itations and shortcoming.
